ACA
BCAX

Acorn Capital Advisors’s Bicara Therapeutics BCAX Stock Holding History

Acorn Capital Advisors’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.1M Sell
643,381
-1
-0% -$22 5.21% 7
2026
Q1 		$12.8M Hold
643,382
– – 3.64% 7
2025
Q4 		$10.8M Hold
643,382
– – 3.67% 9
2025
Q3 		$10.2M Hold
643,382
– – 5.16% 7
2025
Q2 		$5.98M Hold
643,382
– – 3.91% 10
2025
Q1 		$8.38M Buy
643,382
+1
+0% +$13 5.59% 7
2024
Q4 		$11.2M Buy
+643,381
New +$13.4M 6.03% 6

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acorn Capital Advisors's BCAX Position: Q2 2026 in Review

Acorn Capital Advisors reduced its Bicara Therapeutics (BCAX) stake by 0% in Q2 2026, selling an estimated $22 and leaving 643,381 shares worth $19.1M. The position accounts for 5.21% of the portfolio, ranked #7.

Acorn Capital Advisors first reported a position in BCAX in Q4 2024 and has held it in 7 quarters since. 171 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Acorn Capital Advisors held 643,381 shares of Bicara Therapeutics worth $19.1M as of Q2 2026.
  • Acorn Capital Advisors sold 1 Bicara Therapeutics share in Q2 2026, an estimated $22.
  • Bicara Therapeutics made up 5.21% of Acorn Capital Advisors's portfolio in Q2 2026, its #7 holding.
  • Acorn Capital Advisors first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 171 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Acorn Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.